Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The Croatian pharmaceutical company Pliva advanced BPC-157 into a Phase 2 clinical trial for inflammatory bowel disease under the designation PL 14736, which was completed but was never published in full
No fillers
Hsieh et al., Scientific Reports, 2020)
Timing optimization (morning fasted-state dosing) does not change the compounds safety profile
Many people notice an improvement in energy and mental clarity within a few days of their first injection
Description Product Name: BPC-157 Chemical Information: Molecular Formula: C 62 H 98 N 16 O 22 Molecular Weight: 1419.54 g/mol Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Structure Product Description : BPC-157 is a synthetic peptide composed of a defined amino acid sequence produced through controlled peptide synthesis
